Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress
September 19, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Sept. 19, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on three novel antibody cancer therapeutics at the ESMO...
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval
August 11, 2014 07:05 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the initiation of a global, open-label, randomized Phase 2 trial of MM-302, a...
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results
August 11, 2014 07:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call
August 04, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2014 Investor Conference Call and webcast...
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
June 25, 2014 16:05 ET
|
Merrimack Pharmaceuticals
MM-398 in combination with 5-fluorouracil and leucovorin shows statistically significant improvement in overall survival, progression free survival and overall response rate in patients with...
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121
June 19, 2014 16:14 ET
|
Merrimack Pharmaceuticals
Merrimack to Pursue Registration Path for MM-121 and Partnership Opportunities
Top Line Results Released From Final Phase 2 Study in the Collaboration
CAMBRIDGE, Mass., June 19, 2014 (GLOBE...
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
June 17, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that results of the successful Phase 3 NAPOLI-1 study in metastatic pancreatic cancer...
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting
June 02, 2014 16:00 ET
|
Merrimack Pharmaceuticals
CHICAGO, June 2, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 clinical data from studies of MM-151, MM-141, MM-111 and MM-121 was presented at...
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers
June 02, 2014 08:00 ET
|
Merrimack Pharmaceuticals
Studies indicate that 30-50 percent of patients most at risk of progression may benefit from MM-121
Data presented at the 2014 ASCO Annual Meeting from three Phase 2 studies in metastatic lung,...
Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
May 27, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Jefferies 2014...